| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.5 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |